These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 10951138)

  • 1. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
    Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
    Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
    Nevala H; Karenko L; Vakeva L; Ranki A
    Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior.
    Vermeer MH; van Doorn R; Dukers D; Bekkenk MW; Meijer CJ; Willemze R
    J Clin Oncol; 2001 Dec; 19(23):4322-9. PubMed ID: 11731515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
    Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
    Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins.
    Boulland ML; Wechsler J; Bagot M; Pulford K; Kanavaros P; Gaulard P
    Histopathology; 2000 Feb; 36(2):136-44. PubMed ID: 10672058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Nguyen GH; Olson LC; Magro CM
    Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM; Cerroni L
    Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas.
    Dereure O; Portales P; Clot J; Guilhou JJ
    Br J Dermatol; 2000 Dec; 143(6):1205-10. PubMed ID: 11122022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCR-γ expression in primary cutaneous T-cell lymphomas.
    Rodríguez-Pinilla SM; Ortiz-Romero PL; Monsalvez V; Tomás IE; Almagro M; Sevilla A; Camacho G; Longo MI; Pulpillo Á; Diaz-Pérez JA; Montes-Moreno S; Castro Y; Echevarría B; Trébol I; Gonzalez C; Sánchez L; Otín AP; Requena L; Rodríguez-Peralto JL; Cerroni L; Piris MÁ
    Am J Surg Pathol; 2013 Mar; 37(3):375-84. PubMed ID: 23348211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
    Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
    Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
    Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
    Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
    Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.
    Pham-Ledard A; Prochazkova-Carlotti M; Laharanne E; Vergier B; Jouary T; Beylot-Barry M; Merlio JP
    J Invest Dermatol; 2010 Mar; 130(3):816-25. PubMed ID: 19812605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.
    Ni X; Zhang C; Talpur R; Duvic M
    J Invest Dermatol; 2005 Apr; 124(4):741-50. PubMed ID: 15816832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
    Mehdi SJ; Moerman-Herzog A; Wong HK
    BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30-positive cutaneous T-cell lymphoma with concurrent solid tumour.
    Au WY; Yeung CK; Chan HH; Wong RW; Shek TW
    Br J Dermatol; 2002 Jun; 146(6):1091-5. PubMed ID: 12072086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
    Gjerdrum LM; Woetmann A; Odum N; Burton CM; Rossen K; Skovgaard GL; Ryder LP; Ralfkiaer E
    Leukemia; 2007 Dec; 21(12):2512-8. PubMed ID: 17713545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.